Early brain connectivity alterations and cognitive impairment in a rat model of Alzheimer's disease.

abstract：BACKGROUND:Our objectives were to develop a disease progression model for cognitive decline in Alzheimer's disease (AD) and to determine whether disease progression of AD is related to the year of publication, add-on trial design, and geographical regions. METHODS:Placebo-controlled randomized AD clinical trials were ...

journal_title：Alzheimer's research & therapy

authors： Zhang N,Zheng X,Liu H,Zheng Q,Li L

更新日期：2020-05-26 00:00:00

abstract：BACKGROUND:The pathophysiology of neurodegeneration is complex. Its diagnosis requires an early identification of sequential changes in several hallmarks in the brains of affected subjects. The presence of brain pathology can be visualized in the cerebrospinal fluid (CSF) by protein profiling. It is clear that the fiel...

journal_title：Alzheimer's research & therapy

authors： Vanderstichele H,Demeyer L,Janelidze S,Coart E,Stoops E,Mauroo K,Herbst V,François C,Hansson O

更新日期：2017-06-06 00:00:00

abstract：BACKGROUND:The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) was a multicenter randomized controlled trial that reported beneficial effects on cognition for a 2-year multimodal intervention (diet, exercise, cognitive training, vascular risk monitoring) versus control (gene...

journal_title：Alzheimer's research & therapy

authors： Stephen R,Liu Y,Ngandu T,Antikainen R,Hulkkonen J,Koikkalainen J,Kemppainen N,Lötjönen J,Levälahti E,Parkkola R,Pippola P,Rinne J,Strandberg T,Tuomilehto J,Vanninen R,Kivipelto M,Soininen H,Solomon A,FINGER study grou

更新日期：2019-06-04 00:00:00

abstract：BACKGROUND:Neuroinflammation has gained increasing attention as a potential contributing factor in Alzheimer's disease (AD) pathology. A clinical cerebrospinal fluid biomarker capable of monitoring this process during the course of the disease has yet to emerge, chiefly owing to contradictory research findings. In this...

journal_title：Alzheimer's research & therapy

authors： Brosseron F,Traschütz A,Widmann CN,Kummer MP,Tacik P,Santarelli F,Jessen F,Heneka MT

更新日期：2018-02-26 00:00:00

abstract：:Identification of therapeutic targets based on novel mechanistic studies is urgently needed for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and prion disease. Multiple lines of evidence have emerged to suggest that inhibition of the stress-induced endoplasmic reticulum kinase PERK (pro...

journal_title：Alzheimer's research & therapy

authors： Ma T,Klann E

更新日期：2014-05-29 00:00:00

abstract：:Recent trials of statins produced no benefit for subjects with Alzheimer's disease. These negative studies add to a growing list of negative clinical trials. These data point to a need for reevaluating the pathophysiology of late-onset Alzheimer's disease. Late-onset Alzheimer's disease might result from the cumulativ...

journal_title：Alzheimer's research & therapy

authors： Wolozin B

更新日期：2012-01-16 00:00:00

abstract：BACKGROUND:Mild cognitive impairment (MCI) has an uncertain etiology and prognosis and may be challenging for clinicians to discuss with patients and families. Amyloid imaging may aid specialists in determining MCI etiology and prognosis, but creates novel challenges related to disease labeling. METHODS:We convened a ...

journal_title：Alzheimer's research & therapy

authors： Grill JD,Apostolova LG,Bullain S,Burns JM,Cox CG,Dick M,Hartley D,Kawas C,Kremen S,Lingler J,Lopez OL,Mapstone M,Pierce A,Rabinovici G,Roberts JS,Sajjadi SA,Teng E,Karlawish J

更新日期：2017-05-04 00:00:00

abstract：BACKGROUND:Targeting the expression of genes has emerged as a potentially viable therapeutic approach to human disease. In Alzheimer's disease, therapies that silence the expression of tau could be a viable strategy to slow disease progression. METHODS:We produced a novel strain of transgenic mice that could be used t...

journal_title：Alzheimer's research & therapy

authors： Fromholt S,Reitano C,Brown H,Lewis J,Borchelt DR

更新日期：2016-09-05 00:00:00

abstract：BACKGROUND:Dementia has been presenting an imminent public health challenge worldwide. Studies have shown a combination of cognitive and physical trainings may have synergistic value for improving cognitive functions. Daily functional tasks are innately cognitive demanding and involve components found in common exercis...

journal_title：Alzheimer's research & therapy

authors： Law LLF,Mok VCT,Yau MMK

更新日期：2019-12-04 00:00:00

abstract：BACKGROUND:The concept of dependence has been proposed as a unified representation of disease severity to quantify and stage disease progression in a manner more informative to patients, caregivers, and healthcare providers. METHODS:This paper provides a review of the Dependence Scale (DS) as a quantitative measure of...

journal_title：Alzheimer's research & therapy

authors： Zhu CW,Bruinsma BG,Stern Y

更新日期：2018-08-13 00:00:00

abstract：BACKGROUND:Several monoclonal antibodies for the treatment of Alzheimer's disease (AD) have been in development over the last decade. BAN2401 is a monoclonal antibody that selectively binds soluble amyloid β (Aβ) protofibrils. METHODS:Here we describe the first clinical study with BAN2401. Safety and tolerability were...

journal_title：Alzheimer's research & therapy

authors： Logovinsky V,Satlin A,Lai R,Swanson C,Kaplow J,Osswald G,Basun H,Lannfelt L

更新日期：2016-04-06 00:00:00

abstract：BACKGROUND:Amyloid pathology, which is one of the characteristics of Alzheimer's disease (AD), results from altered metabolism of the beta-amyloid (Aβ) peptide in terms of synthesis, clearance, or aggregation. A decrease in cerebrospinal fluid (CSF) level Aβ1-42 is evident in AD, and the CSF ratio Aβ42/Aβ40 has recentl...

journal_title：Alzheimer's research & therapy

authors： Lehmann S,Dumurgier J,Ayrignac X,Marelli C,Alcolea D,Ormaechea JF,Thouvenot E,Delaby C,Hirtz C,Vialaret J,Ginestet N,Bouaziz-Amar E,Laplanche JL,Labauge P,Paquet C,Lleo A,Gabelle A,Alzheimer’s Disease Neuroimaging Initi

更新日期：2020-10-02 00:00:00

abstract：BACKGROUND:Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia in the elderly population. In this study, we used the APP/PS1 transgenic mouse model to explore the feasibility of using diffusion kurtosis imaging (DKI) as a tool for the early detection of microstruct...

journal_title：Alzheimer's research & therapy

authors： Praet J,Manyakov NV,Muchene L,Mai Z,Terzopoulos V,de Backer S,Torremans A,Guns PJ,Van De Casteele T,Bottelbergs A,Van Broeck B,Sijbers J,Smeets D,Shkedy Z,Bijnens L,Pemberton DJ,Schmidt ME,Van der Linden A,Verhoye M

更新日期：2018-01-09 00:00:00

abstract：:The Alzheimer's Drug Discovery Foundation's 13th International Conference on Alzheimer's Drug Discovery was held on 10-11 September 2012 in Jersey City, NJ, USA. This meeting report provides an overview of Alzheimer's Drug Discovery Foundation-funded programs, ranging from novel biomarkers to accelerate clinical devel...

journal_title：Alzheimer's research & therapy

authors： Lane RF,Dacks PA,Shineman DW,Fillit HM

更新日期：2013-02-04 00:00:00

abstract：BACKGROUND:The control of viral infections in the brain involves the activation of microglial cells, the macrophages of the brain that are constantly surveying the central nervous system, and the production of amyloid-beta (Aβ) as an anti-microbial molecule. Recent findings suggest a possible implication of HHV-6A in A...

journal_title：Alzheimer's research & therapy

authors： Bortolotti D,Gentili V,Rotola A,Caselli E,Rizzo R

更新日期：2019-12-12 00:00:00

abstract：BACKGROUND:Amyloid-β 1-42 (Aβ1-42) peptide is a well-established cerebrospinal fluid (CSF) biomarker for Alzheimer's disease (AD). Reduced levels of Aβ1-42 are indicative of AD, but significant variation in the absolute concentrations of this analyte has been described for both healthy and diseased populations. Preanal...

journal_title：Alzheimer's research & therapy

authors： Schauer SP,Mylott WR Jr,Yuan M,Jenkins RG,Rodney Mathews W,Honigberg LA,Wildsmith KR

更新日期：2018-11-28 00:00:00

abstract：INTRODUCTION:Chromosome 9 open reading frame 72 (C9orf72) is an evolutionarily conserved protein with unknown function, expressed at high levels in the brain. An expanded hexanucleotide GGGGCC repeat located in the first intron of the C9orf72 gene represents the most common genetic cause of familial frontotemporal deme...

journal_title：Alzheimer's research & therapy

authors： Satoh J,Tabunoki H,Ishida T,Saito Y,Arima K

更新日期：2012-08-16 00:00:00

abstract：BACKGROUND:There is increasing evidence that dementia risk associated with vascular disorders is age dependent. Large population-based studies of incident dementia are necessary to further elucidate this effect. Therefore, the aim of the present study was to determine the association of vascular disorders with incident...

journal_title：Alzheimer's research & therapy

authors： Legdeur N,van der Lee SJ,de Wilde M,van der Lei J,Muller M,Maier AB,Visser PJ

更新日期：2019-05-17 00:00:00

abstract：INTRODUCTION:There are no empiric data to support guidelines for duration of therapy with antidementia drugs. This study examined whether persistent use of antidementia drugs slows clinical progression of Alzheimer disease (AD) assessed by repeated measures on serial tests of cognition and function. METHODS:Six hundre...

journal_title：Alzheimer's research & therapy

authors： Rountree SD,Chan W,Pavlik VN,Darby EJ,Siddiqui S,Doody RS

更新日期：2009-10-21 00:00:00

abstract：:The strongest known risk factors for late-onset Alzheimer disease (LOAD) remain a positive family history and the APOE epsilon4 allele. van Exel and colleagues used these known risk factors to identify high- and low-risk samples of middle-aged persons in whom they compared levels of inflammatory and vascular risk fact...

journal_title：Alzheimer's research & therapy

authors： Tan ZS,Seshadri S

更新日期：2010-04-12 00:00:00

abstract：BACKGROUND:Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by neuropathologic changes involving beta-amyloid (Aβ), tau, neuronal loss, and other associated biological events. While levels of cerebrospinal fluid (CSF) Aβ and tau peptides have enhanced the antemortem detection of AD-specifi...

journal_title：Alzheimer's research & therapy

authors： Gangishetti U,Christina Howell J,Perrin RJ,Louneva N,Watts KD,Kollhoff A,Grossman M,Wolk DA,Shaw LM,Morris JC,Trojanowski JQ,Fagan AM,Arnold SE,Hu WT

更新日期：2018-09-25 00:00:00

abstract：BACKGROUND:The age gap between participants in trials and patients who could benefit from the drugs studied has been widely documented across different clinical areas. Patients with dementia included in clinical research are systematically younger than those in the general population. We examined the age gap between pa...

journal_title：Alzheimer's research & therapy

authors： Banzi R,Camaioni P,Tettamanti M,Bertele' V,Lucca U

更新日期：2016-08-12 00:00:00

abstract：BACKGROUND:Development of new treatments for Alzheimer's disease (AD) has broadened into early interventions in individuals with modest cognitive impairment and a slow decline. The 11-item version of the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) was originally developed to measure cognition in ...

journal_title：Alzheimer's research & therapy

authors： Podhorna J,Krahnke T,Shear M,Harrison JE,Alzheimer’s Disease Neuroimaging Initiative.

更新日期：2016-02-12 00:00:00

abstract：BACKGROUND:Recent Genome Wide Association Studies (GWAS) have identified novel rare coding variants in immune genes associated with late onset Alzheimer's disease (LOAD). Amongst these, a polymorphism in phospholipase C-gamma 2 (PLCG2) P522R has been reported to be protective against LOAD. PLC enzymes are key elements ...

journal_title：Alzheimer's research & therapy

authors： Magno L,Lessard CB,Martins M,Lang V,Cruz P,Asi Y,Katan M,Bilsland J,Lashley T,Chakrabarty P,Golde TE,Whiting PJ

更新日期：2019-02-02 00:00:00

abstract：BACKGROUND:Imaging agents capable of quantifying the brain's tau aggregates will allow a more precise staging of Alzheimer's disease (AD). The aim of the present study was to examine the in vitro properties as well as the in vivo kinetics, using gold standard methods, of the novel positron emission tomography (PET) tau...

journal_title：Alzheimer's research & therapy

authors： Pascoal TA,Shin M,Kang MS,Chamoun M,Chartrand D,Mathotaarachchi S,Bennacef I,Therriault J,Ng KP,Hopewell R,Bouhachi R,Hsiao HH,Benedet AL,Soucy JP,Massarweh G,Gauthier S,Rosa-Neto P

更新日期：2018-07-31 00:00:00

abstract：BACKGROUND:Global leaders have set an ambitious goal of developing interventions to effectively treat or prevent Alzheimer's disease by 2025. CASE PRESENTATION:Achieving this goal will require clinical trials to test promising interventions, yet Alzheimer's researchers are confronting a clinical trial recruitment cris...

journal_title：Alzheimer's research & therapy

authors： Largent EA,Karlawish J,Grill JD

更新日期：2018-09-27 00:00:00

abstract：BACKGROUND:Intracerebral inoculation of extracts from post-mortem human Alzheimer's disease brains into mice produces a prion-like spreading effect of amyloid-β. The differences observed between these extracts and the synthetic peptide, in terms of amyloid-β internalization and seed and cell-to-cell transmission of cyt...

journal_title：Alzheimer's research & therapy

authors： Pedrero-Prieto CM,Flores-Cuadrado A,Saiz-Sánchez D,Úbeda-Bañón I,Frontiñán-Rubio J,Alcaín FJ,Mateos-Hernández L,de la Fuente J,Durán-Prado M,Villar M,Martínez-Marcos A,Peinado JR

更新日期：2019-06-29 00:00:00

abstract：INTRODUCTION:Mild cognitive impairment (MCI) is classically considered a transitional stage between normal aging and dementia. Non-amnestic MCI (naMCI) patients, however, typically demonstrate cognitive deficits other than memory decline. Furthermore, as a group, naMCI have a lower rate of an eventual dementia diagnosi...

journal_title：Alzheimer's research & therapy

authors： Coutinho AM,Porto FH,Duran FL,Prando S,Ono CR,Feitosa EA,Spíndola L,de Oliveira MO,do Vale PH,Gomes HR,Nitrini R,Brucki SM,Buchpiguel CA

更新日期：2015-09-15 00:00:00

abstract：INTRODUCTION:Weight loss has been described in 20% to 45% of patients with Alzheimer's disease (AD) and has been associated with adverse outcomes. Various mechanisms for weight loss in AD patients have been proposed, though none has been proven. This study aimed to elucidate a mechanism of weight loss in AD patients by...

journal_title：Alzheimer's research & therapy

authors： Droogsma E,van Asselt D,Bieze H,Veeger N,De Deyn PP

更新日期：2015-04-06 00:00:00

abstract：BACKGROUND:Subjective cognitive decline (SCD) is a potential risk factor for dementia. We aimed to investigate the association between SCD and subsequent dementia in a nationwide population-based cohort in South Korea. METHODS:This cohort included 579,710 66-year-old adults who were followed for a total of 3,870,293 p...

journal_title：Alzheimer's research & therapy

authors： Lee YC,Kang JM,Lee H,Kim K,Kim S,Yu TY,Lee EM,Kim CT,Kim DK,Lewis M,Won HH,Jessen F,Myung W

更新日期：2020-05-06 00:00:00